Exhale

The official blog of the Lung Institute.

Lung Institute Announces a Treatment for Pulmonary Sarcoidosis

Announces a Treatment for Sarcoidosis

The Lung Institute is excited to announce the ability to treat another debilitating lung disease. Sarcoidosis is a disease caused by targeted areas of inflammation. It can affect any part of the body, but it typically targets essential organs such as the skin, eyes, lungs, liver and heart. Most commonly, sarcoidosis targets an individual’s lungs resulting in inflammation and difficulty breathing. It is estimated that 90 percent of sarcoidosis cases target the lungs; these cases are aptly named pulmonary sarcoidosis.

Pulmonary Sarcoidosis

Pulmonary sarcoidosis involves small patches of inflamed cell that appear on the lungs and associated lymph nodes. At this point, the lungs become stiff and are unable to hold as much air as healthy lungs. This causes a severe shortness of breath. Depending on severity, pulmonary sarcoidosis can cause permanent scarring in the lungs, which affects the lungs’ ability to move oxygen into the bloodstream.

The potential prognosis associated with sarcoidosis greatly varies. Much like other diseases, early detection makes a huge difference. Unfortunately, due to the symptom overlap of sarcoidosis and many other lung diseases, diagnosing pulmonary sarcoidosis can be challenging.

Previously, sufferers of chronic pulmonary sarcoidosis have faced little to no treatment options. Chronic sarcoidosis is classified as an interstitial lung disease. Historically, individuals with interstitial lung disease had to choose between a highly invasive lung transplant and lung reduction or live with the debilitating progression of the disease. Now, patients have alternative options with cellular therapy.

Cellular Therapy for Sarcoidosis

The Lung Institute uses the patient’s own cells to treat his or her chronic lung disease. Cellular therapy is a minimally invasive procedure that seeks to slow down the progression from the sarcoidosis. With three distinct treatment options available, patients can finally take their health back into their own hands.

About the Lung Institute

At the Lung Institute, we are changing the lives of hundreds of people across the nation through this procedure. We are committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive cellular therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care. For more information, contact us, like us on Facebook, follow us on Twitter or call us today at (800) 729-3065.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.